Bone Biologics Co. (NASDAQ:BBLG) Short Interest Down 13.9% in April

Bone Biologics Co. (NASDAQ:BBLG) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 13,000 shares, a decline of 13.9% from the March 31st total of 15,100 shares. Approximately 2.6% of the company’s shares are sold short. Based on an average trading volume of 80,600 shares, the days-to-cover ratio is presently 0.2 days.

Bone Biologics Price Performance

Shares of BBLG stock traded up $0.01 during mid-day trading on Friday, hitting $1.53. The stock had a trading volume of 28,507 shares, compared to its average volume of 38,713. Bone Biologics has a 12-month low of $1.46 and a 12-month high of $72.00. The firm’s 50-day moving average is $2.22 and its two-hundred day moving average is $3.38.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.